Sevirumab is a human IgG1 monoclonal antibody that targets human cytomegalovirus (HCMV). Sevirumab has been used for the treatment of infections with cytomegalovirus in patients with AIDS.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.